Goldman Sachs Group Inc Cogent Biosciences, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 878,037 shares of COGT stock, worth $6.88 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
878,037
Previous 513,747
70.91%
Holding current value
$6.88 Million
Previous $4.33 Million
118.98%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding COGT
# of Institutions
172Shares Held
113MCall Options Held
56.7KPut Options Held
40.4K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.5MShares$82.1 Million0.31% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.24MShares$72.4 Million8.19% of portfolio
-
Commodore Capital LP New York, NY7.54MShares$59.1 Million6.92% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$57.1 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$54.6 Million9.76% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $516M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...